within Pharmacolibrary.Drugs.ATC.J;

model J05AX25
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.17333333333333334,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.0487,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008666666666666666,
    Tlag           = 30.0
  );

  annotation(Documentation(
    info ="<html><body><p>Baloxavir marboxil is an antiviral prodrug used in the treatment of influenza A and B. It inhibits the cap-dependent endonuclease activity of the viral polymerase, blocking viral replication. Approved and currently used for the treatment of acute, uncomplicated influenza in otherwise healthy adults and adolescents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Baker, J, et al., &amp; Piedra, PA (2020). Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). <i>The Pediatric infectious disease journal</i> 39(8) 700–705. DOI:<a href=&quot;https://doi.org/10.1097/INF.0000000000002747&quot;>10.1097/INF.0000000000002747</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32516282/&quot;>https://pubmed.ncbi.nlm.nih.gov/32516282</a></p></li><li><p>Liu, Y, et al., &amp; De Buck, S (2022). Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals. <i>Clinical and translational science</i> 15(5) 1196–1203. DOI:<a href=&quot;https://doi.org/10.1111/cts.13237&quot;>10.1111/cts.13237</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35176206/&quot;>https://pubmed.ncbi.nlm.nih.gov/35176206</a></p></li><li><p>Kim, Y, et al., &amp; Lee, S (2022). Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects. <i>Clinical and translational science</i> 15(2) 422–432. DOI:<a href=&quot;https://doi.org/10.1111/cts.13160&quot;>10.1111/cts.13160</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34664769/&quot;>https://pubmed.ncbi.nlm.nih.gov/34664769</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AX25;
